INDEX S.

NO 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 CONTENT COMPANY OVERVIEW PRODUCT OVERVIEW FACTORS AFFECTING SUPPLY FACTORS AFFECTING DEMAND MARKET SURVEY RESPONSE OF CONSUMER OBSERVVATION DEMAND SCHEDULE TYPE OF COMPETITION FORM OF MARKET STRUCTURE SHORT RUN EQUILIBRIUM LONG RUN EQUILIBRIUM LEVEL OF BARRIERS AFFECT ON PRICE STRATEGY FINANCIAL STATEMENT PAGE NO 3 6 8 10 12 13 14 15 16 17 18 19 20 22 23

16 17

CSR BIBLIOGRAPHY

29 34

Company Overview

Date of Establishment Revenue Market Cap BnCorporate Address

1983 580.952 ( USD in Millions ) 161393.894597 ( Rs. in Millions ) 159 C S T Road,KalinaSantacruz (East), Mumbai-400098, Maharashtra www.lupinworld.com Chairperson - DeshBandhu Gupta MD - Kamal K Sharma Directors - D K Contractor, DeshBandhu Gupta, K U Mada, K V Kamath, K V Kamoth, Kamal K Sharma, M D Gupta, Marc Desaedeleer, Nilesh Gupta,

Management Details

R A Shah, R V Satam, Richard Zahn, Sunil Nair, Vijay Kelkar, Vinita Gupta

Business operationBackground Pharmaceuticals & Drugs Lupin is a transnational company engaged in development of APIs, generic and branded formulations. It is the largest manufacturer of Tuberculosis drugs in the world. It has onshore and offshore presence of its products in 70 countries. Its manufacturing unit is located in Goa, Tarapur, Ankleshwar, Jammu, Mandideep, Indore,

Key excutive
S.No 1 3 2 4 5 6 7 8 9 10 11 12 13 14 15 Name DeshBandhu Gupta Kamal K Sharma R V Satam D K Contractor Vinita Gupta K U Mada R A Shah M D Gupta Nilesh Gupta Vijay Kelkar K V Kamoth Richard Zahn K V Kamath Vijay Kelkar Richard Zahn Designation Chairman Managing Director Company Secretary Director Director Director Director Executive Director Executive Director Additional Director Additional Director Additional Director Independent Director Independent Director Independent Director

INTRODUCTION OF LUPIN PHARMA

About Lupin Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant market share in key markets in the Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins. The Companys R&D endeavors have resulted in significant progress in its NCE program. The Companys foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Our Drugs and products reach over 70 countries in the world. Today, Lupin has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world The U.S (ranked 8th by prescriptions & growing at 50 %) and Japan (ranked 7th and growing at 23%). The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS - March 2009) and the fastest growing Generic player in South Africa (ranked 6th and growing at 36 % YoY - IMS) For the financial year ended March 2009, Lupin's Consolidated Revenues and Profit after Tax were Rs.39,145 million (US$ 851 million) and Rs. 5015 million (US$ 109 million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Ltd. Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Ltd. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visithttp://www.lupinpharmaceuticals.com.

LupinPharma
The Companys concerted focus on the semi-acute therapy is the crux of the Lupin division, which has enabled the Company to attain market leadership in the Anti-TB segment of IPM. In a Rs.3,162mn Anti-TB market, Lupin commands 48% of the market share. As market leaders in this space, Lupin has embarked on an effort which would redefine the treatment guidelines based on conditions existing in India under the aegis of RIETT-Redefining Indian Expertise Based Tuberculosis Treatment.

Key Products : LupinPharma

Product
R-Cinex AKT Akurit R-CIN G-CIN Combutol Pyzina

Therapeutic segment
Anti-TB Anti-TB Anti-TB Anti-TB Gemifloxacin Ethambutol& Comb. Pyrazinamide Plain

Product Rank in the relevant segment

1 1 1 1 1 1 2

Company

Sales(Rs.Million)

Current Price

Change (%)

P/E Ratio

Market Cap.(Rs.Million)

52-Week High/Low

Sun Pharma Cipla Dr Reddy's Ranbaxy Labs. Glaxosmithkline Phar Lupin Cadila Healthcare Piramal Healthcare Divi'S Lab GlenmarkPharma Biocon Jubilant Life AurobindoPharma TorrentPh Aventis Pharma Matrix Laboratories Pfizer Ipca Laboratories Ster.Biot AstrazenecaPharma Fresenius KabiOncol SunPhaAdv Novartis DishmanPharma Wyeth FDC Strides Arcolab Abbott India

38615.50 49606.00 41589.00 47802.86 18707.67 28985.60 16985.00 23162.60 11905.60 8545.59 9123.37 24285.34 27948.30 11848.92 9744.06 15021.32 8310.44 12956.40 11783.81 3965.06 2620.83 351.42 5994.80 4158.85 2863.60 5763.62 7694.42 7945.57

1546.05 316.75 1289.90 422.90 2038.00 1815.60 612.00 500.65 721.00 271.45 286.55 344.00 882.60 538.90 1873.00 209.35 1050.00 244.05 112.00 841.00 129.05 93.15 611.15 221.90 785.00 91.50 346.40 1072.00

0.03 0.06 -1.59 1.54 -0.30 0.12 2.84 -0.34 4.42 3.84 1.00 1.79 2.66 1.27 1.08 0.00 0.14 -1.09 0.81 1.41 3.16 0.22 3.22 0.29 1.16 1.95 -3.27 -2.27

29.99 23.49 26.16 7.89 32.03 24.87 24.21 23.69 34.04 44.79 22.85 14.78 10.01 21.71 27.89 18.90 22.30 17.19 16.16 39.15 53.38 0.00 16.32 21.25 29.88 13.60 16.57 19.83

320119.09 1846/1070 254164.76 221305.65 175208.31 363/211 1335/598 538/217

173149.91 2271/1086 161393.89 121845.84 104997.75 91238.92 70546.36 56740.00 53659.62 48392.67 45025.94 1844/755 838/188 600/250 728/452 304/199 311/164 373/155 990/326 555/164

42675.74 1968/1030 32729.53 31288.75 30899.92 27796.84 20732.50 19794.28 19251.47 18923.99 17854.24 17630.77 16718.50 15587.78 15000.37 227/165 1125/711 304/85 146/90 1109/570 163/42 105/57 633/385 275/136 850/500 96/37 371/98 1210/415

Unichem Lab Wockhardt Solvay Pharma PlethicoPharma Panacea Biotec Merck Orchid Chemicals Nectar Lifesciences JB Chem&Pharma Elder Pharma Shilpa Medicare Alembic Indoco Remedies NatcoPharma Bliss GVS Parenteral Drugs Zenotech Lab. Fulford India Morepen Labs Ankur Drugs Suven Life Sciences Piramal Life Science Sequent Scientific Zandu Realty Shasun Chemicals TTK Healthcare Surya Pharma Alchemist Twilight Litaka Phar Venus Remedies Ajanta Pharma

6568.67 15038.91 2417.26 4721.43 7734.17 4731.10 11914.40 7279.68 6767.61 6200.22 1359.55 10940.85 3506.35 2696.92 1329.56 2260.74 60.23 1947.00 1641.04 9653.21 1400.11 21.30 1060.62 877.46 4708.34 2196.47 7229.24 3864.66 3704.43 2640.94 3194.77

403.40 121.10 2519.95 351.70 173.95 635.00 140.25 37.85 81.10 368.95 297.40 47.05 400.95 162.00 42.60 193.00 112.50 990.15 7.90 183.40 28.35 130.50 139.95 3540.00 58.50 342.00 172.85 185.00 107.25 266.50 183.30

1.34 0.67 3.81 0.03 2.72 1.19 2.86 0.00 1.31 5.28 1.47 1.62 0.14 2.11 2.40 -2.03 1.35 1.59 2.33 4.80 3.09 4.99 0.14 -0.65 2.45 -2.56 3.01 0.57 3.08 3.11 2.75

10.75 0.00 28.12 15.41 14.15 14.42 0.00 10.70 6.69 11.96 13.59 29.89 11.69 9.72 10.46 14.25 0.00 24.25 0.00 3.78 45.78 0.00 26.57 8.66 22.60 29.87 3.25 13.26 6.63 4.83 7.32

14357.19 13165.14 12257.40 11977.84 11319.82 10416.94 9604.78 8488.28 6753.75 6608.61 6455.28 6181.79 4919.60 4465.67 4290.90 3821.82 3821.65 3801.14 3472.66 3384.78 3204.75 3163.60 3065.44

453/189 201/107 3600/650 405/151 248/100 687/371 239/78 44/15 96/37 408/218 363/64 56/35 442/148 184/71 51/15 255/57 139/93 1150/436 12/7 251/100 37/18 152/50 164/35

2873.40 12800/2513 2758.73 2725.86 2427.79 2252.43 2214.32 2194.75 2088.80 72/18 435/101 196/75 216/82 132/33 312/182 212/73

Themis Medicare Granules India Amrutanjan Health IndSwiLab Phaarmasia SMS Pharma MarksansPharma Vivimed Labs Jupiter Bioscience Aarti Drugs Anu's Labs Kilitch Drugs Sharon BioMedicine Kopran IndSwiLtd Wanbury AnuhPharma RPG Life Sciences Bharat Immunological Ambal Sarabhai Hester Biosciences Albert David Syncom Healthcare BafnaPharma Adinath Bio-Lab Lyka Labs DIL JagsonpalPharma Neuland Lab. HiranOrgochem Kerala Ayurveda

1998.98 2538.74 906.60 5834.95 111.00 2445.92 1995.30 1514.89 1429.28 3765.03 1597.09 1290.12 4197.91 1186.42 5870.55 1672.88 1205.13 1392.43 71.08 625.10 301.60 2056.92 605.65 457.99 218.18 1520.75 17.68 1361.98 3067.22 1885.67 179.85

245.80 96.50 613.00 66.50 253.00 167.95 4.35 156.75 81.95 112.25 5.90 100.00 115.00 32.10 29.50 72.45 377.85 70.80 18.75 10.12 136.50 124.05 39.20 43.60 2.86 29.25 263.00 21.20 94.95 9.55 45.35

3.47 1.85 0.14 2.23 -4.99 2.41 2.35 1.59 0.43 3.08 8.66 3.31 2.68 4.05 1.03 1.26 2.29 5.12 3.02 1.30 -0.73 1.39 1.29 3.20 -4.35 2.63 5.05 6.53 2.10 1.38 0.00

10.58 7.94 14.23 3.77 0.00 71.17 707.32 12.96 4.90 5.62 7.67 10.84 5.30 11.60 3.03 0.00 7.97 9.40 0.00 4.14 12.14 6.80 17.07 14.19 34.79 26.45 7.50 5.70 0.00 0.00 0.00

1912.40 1900.42 1854.81 1811.80 1727.22 1642.49 1563.18 1537.58 1510.29 1318.62 1311.45 1277.97 1182.37 1144.62 1085.61 1051.02 1028.41 1014.89 785.88 765.57 713.79 698.27 677.25 675.21 660.02 615.03 574.10 521.34 501.87 494.58 478.70

301/60 115/52 1345/324 80/34 344/253 190/109 8/4 175/65 105/52 128/48 27/5 157/59 144/42 37/9 37/16 96/44 465/172 92/26 26/17 17/10 156/76 143/62 162/39 45/19 21/3 41/17 309/146 27/11 160/92 13/4 66/30

Gufic Biosciences Arvind Remedies Smruthi Organics AhlconParenterals Lincoln Pharma Celestial Biolabs Rubra Medicaments Syncom Formulations Alpa Lab Elder

515.76 2178.88 729.54 378.30 1140.18 192.51 10.21 575.64 1201.01 508.08

6.13 1.73 105.25 54.25 32.50 31.55 61.85 26.50 14.65 74.35

3.03 5.49 0.19 0.00 2.52 5.34 4.92 4.33 -0.68 -1.20

36.13 5.75 7.22 9.19 4.58 5.96 0.00 6.47 38.94 0.00

460.23 426.48 400.81 390.61 358.55 352.90 322.36 315.22 310.35 301.00

11/4 3/1 132/38 58/22 39/19 45/14 59/10 34/15 20/11 111/26

Maxter
As the face of Lupin in the critical care segment and AntiInfectives, Maxter Division emulates the Companys objective of saving more lives. As a spin-off from Endeavour, the division was launched in 2006-07. The inception of Maxter has empowered Lupin to tap unexplored opportunities in chosen therapeutic area, with an unwavering focus. This division focuses on giving the best therapeutic care in the critical care segment. It reaches out to interventionists and super-specialty doctors and has also ventured into the field of wound management.

Key Products :Maxter

Product Merotrol Tazar Ceff Cetil Cefantral

Product Rank in the Therapeutic segment relevant segment Meropenem Piperacillin + Tazobactam Cephalexin Oral Solids Cefuroxime Oral Solids CefotaximeInjectibles 1 1 3 5 9

PRODUCTS OF LUPIN PHARMA

LupinPharma Brand Name Molecule Therapy Segment

AKT 2

Each Kit contains RIFAMPICIN 450 MG+ ISONIAZID - 300 MG Each Kit contains RIFAMPICIN 450 MG + ISONIAZID - 300 MG+ ETHAMBUTOL - 800 MG Each Kit contains RIFAMPICIN 450 MG + ISONIAZID - 300 MG + ETHAMBUTOL - 800 MG + PYRAZINAMIDE - 1500 MG Each tablet contains RIFAMPICIN - 150 MG+ISONIAZID -100 MG + ETHAMBUTOL - 267 MG + PYRAZINAMIDE - 500 MG Each tablet contains RIFAMPICIN - 150 MG + ISONIAZID - 75 MG +ETHAMBUTOL - 275 MG + PYRAZINAMIDE - 400 MG Each tablet contains RIFAMPICIN - 150 MG + ISONIAZID - 75 MG + ETHAMBUTOL -275 MG Each tablet contains RIFAMPICIN - 150 MG + ISONIAZID -75 MG

TUBERCULOSTATIC

AKT3

TUBERCULOSTATIC

AKT4

TUBERCULOSTATIC

AKT FD

TUBERCULOSTATIC

AKURIT4

TUBERCULOSTATIC

AKURIT3

TUBERCULOSTATIC

AKURIT

TUBERCULOSTATIC

Each tablet contains RIFAMPICIN - 60 MG + AKURIT Z KID ISONIAZID -30 MG + PYRAZINAMIDE -150 MG AKURIT KID COMBUTOL 200 COMBUTOL 400 COMBUTOL Each tablet contains RIFAMPICIN - 60 MG + ISONIAZID - 30 MG Each tablet contains ETHAMBUTOL - 200 MG Each tablet contains ETHAMBUTOL - 400 MG Each tablet contains

TUBERCULOSTATIC

TUBERCULOSTATIC

TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC

600 COMBUTOL 800 COMBUTOL 1000 COMBUNEX

ETHAMBUTOL - 600 MG Each tablet contains ETHAMBUTOL - 800 MG Each tablet contains ETHAMBUTOL - 1000 MG Each tablet conatins ETHAMBUTOL - 800 MG + ISONIAZID - 300 MG Each tablet contains PYRAZINAMIDE - 300 MG Each tablet contains PYRAZINAMIDE - 500 MG Each tablet contains PYRAZINAMIDE - 750 MG Each tablet contains PYRAZINAMIDE - 1000 MG Each capsule contains RIFAMPICIN - 150 MG Each capsule contains RIFAMPICIN - 300 MG Each capsule contains RIFAMPICIN - 450 MG Each capsule contains RIFAMPICIN - 600 MG Each 5ml containsRIFAMPICIN 100 MG Eah tablet contains RIFAMPICIN - 450 MG+ ISONIAZID - 300 MG Each tablet contains RIFAMPICIN - 600 MG +ISONIAZID - 300 MG TUBERCULOSTATIC TUBERCULOSTATIC

TUBERCULOSTATIC

PYZINAKID PYZINA 500 PYZINA 750 PYZINA 1000 R-CIN 150 MG R-CIN 300 MG R-CIN 450 MG R-CIN 600 MG R-CIN SYRUP R-CINEX 450 MG R-CINEX 600 MG R-CINEX KID R-CINEX Z

TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC

TUBERCULOSTATIC

Eah tablet containsRIFAMPICIN TUBERCULOSTATIC 100 MG + ISONIAZID - 100 MG Eah tablet contains RIFAMPICIN TUBERCULOSTATIC

- 225 MG + ISONIAZID - 150 MG + PYRAZINAMIDE - 750MG RCINEX E Eah tablet contains RIFAMPICIN - 450+ ISONIAZID - 300 MG + ETHAMBUTOL - 800 MG Eah tablet contains RIFAMPICIN - 225 MG + ISONIAZID - 150 MG +ETHAMBUTOL - 400 MG + PYRAZINAMIDE - 750 MG Eah tablet contains RIFAMPICIN - 100 MG + ISONIAZID - 50 MG TUBERCULOSTATIC

RCINEX EZ

TUBERCULOSTATIC

RCINEX DT

TUBERCULOSTATIC

Eah tablet contains RIFAMPICIN RCINEX Z KID - 100 MG + ISONIAZID - 50 MG + PYRAZINAMIDE - 300 MG RINIZIDE FORTE DT ETHIDE TABLETS PETHIDE Q-PAS CYCLORIN 250 MG EFFICIN 500MG EFFICIN 750MG EFFICIN 1000MG RIBUTIN BENZ E-CEF 125 Eah tablet contains RIFAMPICIN -150 MG + ISONIAZID -100 MG + PYRAZINAMIDE -500 MG Eah tablet contains ETHIONAMIDE - 250 MG Eah tablet contains PROTHIONAMIDE - 250 MG PARA-AMINOSALICYLIC ACID Each capsule contains CYCLOSERINE - 250 MG Each vial contains KANAMYCIN - 500 MG Each vial contains KANAMYCIN - 750 MG Each vial contains KANAMYCIN - 1000 MG

TUBERCULOSTATIC

TUBERCULOSTATIC

TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC TUBERCULOSTATIC

Eah tablet contains RIFABUTIN HIV-TUBERCULOSTATIC 150 MG Each pearl contains BENZONATATE - 100 MG Each vial contains COUGH SUPRESSANT ANTI-INFECTIVES/ ANTI-

MG E-CEF 250 MG E-CEF 500 MG E-CEF 1000 MG ECEF OD

CEFTRIAXONE - 125 MG Each vial contains CEFTRIAXONE - 250 MG Each vial contains CEFTRIAXONE - 500 MG Each vial contains CEFTRIAXONE - 1000 MG

BIOTICS ANTI-INFECTIVES/ ANTIBIOTICS ANTI-INFECTIVES/ ANTIBIOTICS ANTI-INFECTIVES/ ANTIBIOTICS

Each vial contains CEPHALEXIN ANTI-INFECTIVES/ ANTI- 250 MG BIOTICS Each vial contains CEFTRIAXONE+SULBACTAM 1500 MG Each vial contains CEFTRIAXONE+SULBACTAM 750 MG Each vial contains CEFTRIAXONE+SULBACTAM 375 MG Eah tablet contains GEMIFLOXACIN - 320 MG Eah tablet contains LEVOFLOXACIN - 750 MG Eah tablet contains LEVOFLOXACIN - 250 MG + ORNIDAZOLE - 500 MG ANTI-INFECTIVES/ ANTIBIOTICS ANTI-INFECTIVES/ ANTIBIOTICS ANTI-INFECTIVES/ ANTIBIOTICS ANTI-INFECTIVES/ ANTIBIOTICS ANTI-INFECTIVES/ ANTIBIOTICS ANTI-INFECTIVES/ ANTIBIOTICS

ECEF S 1.5

ECEF S 750MG ECEF S 375 MG GCIN LCIN 750

LCIN OZ

LCIN IV RTIST 300MG RTIST SUSP NECTERA POWDER DEFNALONE

Each vial contains ANTI-INFECTIVES/ ANTILEVOFLOXACIN - 500MG/100ML BIOTICS Each capsule contains CEFDINIR - 300 MG Each 5ml contains CEFDINIR 125MG/5ML Each 3gm powder contains 500mg COLOSTRUM (28%IgG) 90gm TIN Each tablet conatins ANTI-INFECTIVES/ ANTIBIOTICS ANTI-INFECTIVES/ ANTIBIOTICS NUTRACEUTICAL GLUCOCORTICOID / STERIOD

1MG DEFNALONE 6MG DEFNALONE 24MG DEFNALONE 30MG LUPIGEST 100 LUPIGEST 200 YAMINI MEFNIL

DEFLAZACORT -1 MG Each tablet contains DEFLAZACORT - 6 MG Each tablet contains DEFLAZACORT - 24 MG Each tablet contains DEFLAZACORT - 30 MG NATURAL PROGESTERONE 100 MG NATURAL PROGESTERONE 200 MG GLUCOCORTICOID / STERIOD GLUCOCORTICOID / STERIOD GLUCOCORTICOID / STERIOD

Hormones

DROSPIRENONE - 3 MG +ETHINYLESTRADIOL - 0.03 MG Hormones MIFEPRISTONE - 200 MG

MISONIL -200 MISOPROSTOL - 200 MCG MCG MISONIL -25 MCG FASTRACE MISOPROSTOL - 25 MCG PREGNANCY KIT

Hormones

Pregnancy Detection Hormones

OVIPHENE-25 CLOMIFENE CITRATE - 25 MG OVIPHENE-50 CLOMIFENE CITRATE - 50 MG LUPI-HMG 75IU LUPI-HMG 150IU LUPI-FSH 75IU LUPI-FSH 150IU LUPI-HCG 2000 LUPI-HCG 5000 HUMAN MENOPAUSAL GONADOTROPIN INJ. 75 I.U. HUMAN MENOPAUSAL GONADOTROPIN INJ. 150 I.U. FOLLICLE STIMULATING HORMONE INJ. 75 I.U. FOLLICLE STIMULATING HORMONE INJ. 150 I.U. HUMAN CHORIONIC GONADOTROPIN INJ. 2000 I.U. HUMAN CHORIONIC GONADOTROPIN INJ. 5000 I.U.

Hormones

Hormones

Hormones

LUPI-HCG 10000

HUMAN CHORIONIC GONADOTROPIN INJ.10000 I.U.

MindVision
Brand Name
Stalopam

Molecule
Escitalopram 5mg Escitalopram 10mg Escitalopram 20mg

Therapy Segment
Antidepressant Antidepressant Antidepressant Antidepressant Nootropic Nootropic Nootropic Nootropic Antiepileptics Antiepileptics

Stalopam Plus Citistar

Escitalopram 10mg + Clonazepam 0.5mg Citicoline 500mg Citicoline (250mg/ml) Citicoline 500mg (250mg/ml) Citicoline 1000 mg Sustained Release tablets

Epilive

Levetiracetam 250mg Tablets Levetiracetam 500mg Tablets

Levetiracetam 750mg Tablets Lovax Oxcarbazepine 150mg Oxcarbazepine 300mg Oxcarbazepine 600mg Lovax OD Oxcarbazepine 300mg Extended Release Oxcarbazepine 600mg Extended Release Dayo OD Divalproex 250mg Divalproex 500mg Divalproex 750mg Pregadoc Pregabaline 75mg Pregabaline 150mg Pregadoc M Pregabalin 75mg + Mecobalamin 750mcg Capsules Pregabalin 150mg + Mecobalamin 750mcg Capsules Amigold Amisulpride 50mg Amisulpride 100mg Amisulpride 200mg Jolyon - MD Olanzepine 5mg Olanzepine 7.5mg Olanzepine 10mg Olanzepine 15mg Arzu Aripiprazole 15mg Aripiprazole 10mg Aripiprazole 30mg Placidin Quetiapine 100mg Quetiapine 200mg

Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Antiepileptics Agent for neurpathic pain Agent for neurpathic pain Agent for Neuropathic Pain

Agent for Neuropathic Pain Antipsychotic Antipsychotic Antipsychotic Antipsychotic Antipsychotic Antipsychotic Antipsychotic Antipsychotic Antipsychotic Antipsychotic Antipsychotic Antipsychotic

Quetiapine 25mg PlaciDox Diazepam 10mg Diazepam 2mg Diazepam 5mg DULOT Duloxetine 20mg Duloxetine 30mg Anxicalm Alprazolam 0.25mg Alprazolam 0.5mg Goodnoct XR Zolpidem 6.25mg Extended Release Tablets Zolpidem 12.5mg Extended Release Tablets Tolifast Movexol Tolperisone 150mg Tablets Pramipexole 0.25mg Tablets Pramipexole 0.5mg Tablets Pramipexole 1mg Tablets Fibril Fibril SF Ribavin 200 mg Ispaghula husk Ispaghula husk Ribavirin 200mg Ribavirin 50mg Alzidoc Donepezil 5mg Tablets Donepezil 10 mg Tablets Restfull Edastar

Antipsychotic Tranquilizers Tranquilizers Tranquilizers Antidepressant Antidepressant Tranquilizers Tranquilizers Hypnotic Hypnotic Muscle Relaxant Drug for Parkinson's Disease Drug for Parkinson's Disease Drug for Parkinson's Disease Laxatives Laxatives Hepatitis C Hepatitis C Drug for Alzheimer's Disease Drug for Alzheimer's Disease

Flupentixol 0.5mg + Melitracen Anxiolytic 10mg Tablets Edaravone injection 1.5 mg/mL(20 mL) Other CNS drugs

Pinnacle
For more details on the below given information, kindly visit www.epinnacleworld.com

Brand Name
TONACT 5 TONACT 10 TONACT 20 TONACT 40 TONACT 80 TONACT PLUS TONACT FORTE TONACT 10MG EZ

Molecule
Atorvastatin Atorvastatin Atorvastatin Atorvastatin Atorvastatin Atorvastatin + Niacin Atorvastatin + Niacin Atorvastatin +Ezetimibe

Therapy Segment
Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer

TONACT 20mg EZ TONACT TG TONACT 10 MP TRITONACT

Atorvastatin +Ezetimibe Atorvastatin + Fenofibrate Atorvastatin Atorvastatin + Fenofibrate + Ezetimibe Atorvastatin + Telmisartan Ramipril Ramipril Ramipril Ramipril Ramipril + Amlodipine Ramipril +Hctz Ramipril +Hctz Torsemide Torsemide Torsemide Torsemide Torsemide

Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer + AntiHypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Diuretic Diuretic Diuretic Diuretic Diuretic

TONACT-TM RAMISTAR 1.25 RAMISTAR 2.5MG RAMISTAR 5MG RAMISTAR 10MG RAMISTAR A 2.5 RAMISTAR H 2.5 RAMISTAR H 5 RETORLIX 5 RETORLIX 10 RETORLIX 20 RETORLIX 100 RETORLIX injection

RETORLIX SP VALENT 40 VALENT 80mg VALENT H VALENT 160 VALENT R PINOM 10 PINOM 20 PINOM 40 MG PINOM H PINOM A 20 MG CLOPITAB 75mg CLOPITAB 150 CLOPITAB A 75 CLOPITAB A 150 CILODOC 50 CILODOC 100 FAXIMAB 10MG/5 ML VIAL

Torsemide + Spironolactone Valsartan Valsartan Valsartan + Hctz Valsartan Valsartan +Ramipril Olmesartan Olmesartan Olmesartan Olmesartan + Hctz Olmesartan + Amlodipine Clopidogrel Clopidogrel Clopidogrel + Aspirin Clopidogrel + Aspirin Cilostazol Cilostazol Abciximabinj

Diuretic Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Antiplatelet Antiplatelet Antiplatelet Antiplatelet Antiplatelet Antiplatelet Antiplatelet

LUPENOX 20MG LUPENOX 40MG LUPENOX 60MG PLANEP ISONORM 10 ISONORM 20 ISONORM 30 SR IVABRAD 5MG IVABRAD 7.5MG DOFUSE Injection LUPIDIP 2.5/5/10 mg

Enoxaparin Enoxaparin Enoxaparin Eplerenone IsosordibeMononitrate IsosordibeMononitrate IsosordibeMononitrate Ivabradine Ivabradine Dobutamine Amlodipine

Anticoagulant Anticoagulant Anticoagulant Diuretic Antianginal Antianginal Antianginal Antianginal Antianginal Positive Ionotropes Anti-Hypertensive

LUPIBOSE 62.5/125 Bosentan mg HARTY Resveratrol + Grape seed extract

Pulmonary Anti-Hypertensive

Nutritional Supplement

Pinnacle CVN (CARDIOVASCULAR NEPHROLOGY)

Brand Name ATENOVA 25 Molecule Atenolol Therapy Segment Anti-Hypertensive

MG ATENOVA 50 MG ATENOVA 100 MG EZEDOC FRUSELAC FRUSELAC DS ISONORM 10 ISONORM 20 Atenolol Atenolol Ezetimibe Frusemide + Spironolactone Frusemide + Spironolactone IsosordibeMononitrate IsosordibeMononitrate Anti-Hypertensive Anti-Hypertensive Cholesterol Reducer Diuretic Diuretic Anti-Anginal Anti-Anginal Anti-Anginal Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive

ISONORM 30 SR IsosordibeMononitrate LIPRIL 2.5mg LIPRIL 5mg LIPRIL 10mg LIPRIL AM LIPRIL H NEBISTAR 2.5mg NEBISTAR 5mg NEBISTAR SA NEBISTAR H Lisinopril Lisinopril Lisinopril

Lisinopril + Amlodipine Anti-Hypertensive Lisinorpil + Hydrochlorothiazide Nebivolol Nebivolol Nebivilol + samlodipine Nebivilol + Hydrochlorothiazide Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive

STARPRESS XL Metoprolol 100

STARPRESS XL Metoprolol 25 STARPRESS XL Metoprolol 50 STARPRESS H 25 XL STARPRESS H 50 XL Metoprolol + Hydrochlorothiazide Metoprolol + Hydrochlorothiazide

Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive Anti-Hypertensive+Anti-Anginal Anti-Hypertensive+Anti-Anginal Anti-Hypertensive Anti-Hypertensive Anti-Anginal Cholesterol Reducer Cholesterol Reducer Cholesterol Reducer Antiplatelet Antiplatelet

STARPRESS AM Metoprolol + XL 30 Amlodipine STARPRESS AM Metoprolol + XL Amlodipine STARPRESS MN Metolprolol + XL 30 Isosorbidemononitrate STARPRESS MN Metolprolol + XL 60 Isosorbidemononitrate STARPRESS R XL 25 STARPRESS R XL 50 RANCAD Metoprolol + Ramipril Metoprolol + Ramipril Ranolazine

NOVASTAT 5MG Rosuvastatin NOVASTAT 10MG NOVASTAT 20MG FLETA BOLUS INJ FLETA INFUSION Rosuvastatin Rosuvastatin Eptifibatide Eptifibatide

TIROFUSE LUPIFLO 7.5 L LUPIFLO 15 L SENACEPT

Tirofiban Recombinant Streptokinase Recombinant Streptokinase Cinacalcet HCL

Antiplatelet Fibrinolytic Fibrinolytic Calcimimetic

Endeavour
Brand Name
CALUFT CAPS

Molecule

Therapy Segment

CALCIUM CARBONATE + CALCITRIOL ANTI+ ZINC + MAGNESIUM + BORON OSTEOPOROSIS CALCIUM CITRATE MALEATE + VIT.D3 CALCIUM + ZINC + MANGANESE + MAGNESIUM PREPARATION + COPPER ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE Anti-bacterial (CEPHALOSPORIN

CALUFT-G

CEFAXONE 1000 CEFTRIAXONE IM/IV Mg CEFAXONE 125 Mg CEFAXONE 250 Mg CEFAXONE 500 Mg CEFFOREN CEFTRIAXONE IM/IV CEFTRIAXONE IM/IV CEFTRIAXONE IM/IV CEFDITOREN

ORAL) CO-Q-DENT CO-Q-DENT CO-Q-10 CO-Q-10 PHENYLPROPANOLAMINE 25MG + CETIRIZINE 5MG + PARACETAMOL 500MG CETRIZINE CETRIZINE CETRIZINE 5MG + PSEUDOEPHEDRINE 30MG/5ML AMBROXOL 15MG + R-SALBUTAMOL 1MG + GUAIPHENESIN 50 MG + MENTHOL 0.5MG DEXTROMETHORPHAN + CETRIZINE + PSEUDOEPHEDRINE + MENTHOL CEFPODOXIME HERBAL TOOTHPASTE HERBAL TOOTHPASTE COLD PREPARATION ANTI-HISTAMINE ANTI-HISTAMINE COLD PREPARATION COUGH PREPARATION COUGH PREPARATION Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL)

CZ-3 COLD CZ-3 SYRUP CZ-3 TABLET CZ-COLD

CZ-EX

CZ-TUS

DOXCEF 100

DOXCEF 100 DRY SYRUP

CEFPODOXIME

DOXCEF 200

CEFPODOXIME

DOXCEF 50 DRY SYRUP

CEFPODOXIME

DOXCEF 50 DT

CEFPODOXIME

DOXCEFF DT 100 CEFPODOXIME MG

EUBIOZ CAP EUBIOZ SACHET HEPP FORTE SYRUP LUPIN TAZOX 250 MG LUPIN TAZOX 1 GM

PREBIOTIC PROBIOTIC COMBINATION PREBIOTIC PROBIOTIC COMBINATION CEFTRIAXONE + TAZOBACTAM CEFTRIAXONE + TAZOBACTAM

Gastro-intestinal Gastro-intestinal HAEMATINIC ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE ANTI INFECTIVE INJECTABLE Anti-diarrhoeal Anti-diarrhoeal Anti-diarrhoeal Anti-diarrhoeal Anti-diarrhoeal CEPHALOSPORIN INJ CEPHALOSPORIN INJ CEPHALOSPORIN INJ Anti-bacterial (CEPHALOSPORIN

LUPINEM 500 MG IMIPENEM + CILASTATIN MAGNOVA 1G MAGNOVA 250 MG MAGNOVA 5G NIZONIDE NIZONIDE DT TABLET NIZONIDE SUSP NIZONIDE-O NIZONIDE-O SUSP Novapime 1000 mg NOVAPIME 250 MG INJ Novapime 500 mg ODOXIL 125 DT CEFEPIME+TAZOBACTAM CEFEPIME+TAZOBACTAM CEFEPIME+TAZOBACTAM NITAZOXANIDE NITAZOXANIDE NITAZOXANIDE NITAZOXANIDE + OFLOXACIN NITAZOXANIDE + OFLOXACIN CEFEPIME CEFEPIME CEFEPIME CEFADROXIL

ORAL) ODOXIL 250 DT TABLETS ODOXIL 250 PREMIX CEFADROXIL Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) Anti-bacterial (CEPHALOSPORIN ORAL) NEUROTROPIC NEUROTROPIC ORAL ANTIINFECTIVE Anti-peptic Ulcerant Anti-peptic Ulcerant Anti-peptic Ulcerant Anti-peptic Ulcerant Gastro-intestinal Anti-peptic Ulcerant

CEFADROXIL

ODOXIL 500 Mg

CEFADROXIL

ODOXIL DS

CEFADROXIL

ODOXIL OD

CEFADROXIL

ODOXIL PREMIX

CEFADROXIL

ODOXIL SUSPENSION OPTINEURON INJ OPTINEURON TABS PERCIN RABLET 10 MG RABLET 10 MG RABLET 20 MG RABLET 20 MG RABLET D caps RABLET I.V.

CEFADROXIL

VITAMIN B COMPLEX VITAMIN B COMPLEX PRULIFLOXACIN 600MG RABEPRAZOLE RABEPRAZOLE RABEPRAZOLE RABEPRAZOLE RABEPRAZOLE + DOMPERIDONE RABEPRAZOLE IV

SALES (1 RABLET IT RCIFAX RCLONAC TABLET 10 X RESNER INJ RESNER SOFT CAPSULES SIGNOFLAM -P TAB SIGNOFLAM TABLET SOFTOVAC SOFTOVAC SF TOPCERIN ULYSES 150 MG ULYSES 300 MG VIDA-25 VIDA-50 VIDA-H RABEPRAZOLE+ITOPRIDE RIFAXIMIN Gastro-intestinal GI Anti-bacterial (RIFAMPICIN DERIVATIVE) NSAID + APU NEUROTROPIC NEUROTROPIC NSAIDS NSAIDS LAXATIVE LAXATIVE OTHER PLAIN ANTI ARTHRITIC HEPATOPROTECTIVE HEPATOPROTECTIVE ANTI HYPERTENSIVE ANTI HYPERTENSIVE

DICLOFENAC SR+ RABEPRAZOLE MECOBALAMINE MECOBALAMINE ACECLOFENAC ACECLOFENAC ISABGOL COMBINATION ISABGOL COMBINATION DIACEREIN URSODESOXYCHOLIC ACID URSODESOXYCHOLIC ACID LOSARTAN LOSARTAN

LOSARTAN+HYDROCHLOROTHIAZIDE ANTI HYPERTENSIVE

Lupin Diabetes Care

Brand Name
Gluconorm SR Gluconorm SR 1g Gluconorm G1 Gluconorm G2 Gluconorm P15 Gluconorm P30

Molecule
Metformin 500 mg extended release Metformin 1 gm extended release Metformin 500 mg ER + Glimepiride 1 mg Metformin 500 mg ER + Glimepiride 2 mg Metformin 500 mg ER + Pioglitazone 15 mg Metformin 500 mg ER + Pioglitazone 30mg

Therapy segment
Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management

Metformin 500 mg ER + Gluconorm PGPioglitazone 15 mg + Glimepiride 1 1 mg

Diabetes Management

Metformin 500 mg ER + Gluconorm PGPioglitazone 15 mg + Glimepiride 2 2 mg Gluconorm G1 Forte Gluconorm G21 Forte Glutide CR 30MG Glutide CR 60MG Glador 1 Glador 2 Glador 3 Glador 4 Lipril 2.5 Lipril 5 Lipril 10 Lipril AM Lipril H Matilda Plus Matilda Forte Metformin 1 gm ER + Glimepiride 1mg Metformin 1 gm ER + Glimepiride 2 mg Gliclazide Controlled Release 30 mg Gliclazide Controlled Release 60 mg Glimepiride 1 mg Glimepiride 2 mg Glimepiride 3 mg Glimepiride 4 mg Lisinopril 2.5 mg Lisinopril 5 mg Lisinopril 10 mg

Diabetes Management

Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension

Lisinopril 5 mg + Amlodipine 5 mg Diabetic Hypertension Lisinopril 5 mg + Hydrochlorothiazide 12.5 mg Mecobalamin 750 mcg + ALA 100 mg+ Pyridoxine 3mg + Folic aci Diabetic Hypertension Diabetic Neuropathy Management

Mecobalamin 1500 mcg + ALA 200 Diabetic Neuropathy Management mg + Folic acid 1.5 mg + Pyri Mecobalamin 750 mcg + ALA 100mg + GLA 60 mg + Benfothiamin Diabetic Neuropathy Management

Matilda AF

Matilda ER Matilda Inj 1x1ml Misobit 25

Mecobalamin 1500 mcg + Diabetic Neuropathy Management Pyridoxine 20mg + Folic acid 5mg Mecobalamin 500 mcg I.M./I.V. Miglitol 25 mg Diabetic Neuropathy Management Diabetes Management

Misobit 50 Misobit MD 25 Misobit MD 50 Path 15mg Path 30 mg Path G1 Path G2 Retorlix 5 Retorlix 10 Retorlix 20 Retorlix 100 Retorlixinj Retorlix SP 5 Retorlix SP 10 Starstat 5 Starstat 10 Starstat 20 Starstat 40 Starstat EZ 10 Starstat EZ 20 Telista 20 Telista 40 Telista 80

Miglitol 50 mg Miglitol Mouth Dissolving 25 mg Miglitol Mouth Dissolving 50 mg Pioglitazone 15 mg Pioglitazone 30 mg Pioglitazone 15 mg + Glimepiride 1 mg Pioglitazone 15 mg + Glimepiride 2 mg Torsemide 5 mg Torsemide 10 mg Torsemide 20 mg Torsemide 100 mg Torsemide Injection 10mg/ml

Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension

Torsemide 5 mg + Spironolactone Diabetic Hypertension 50 mg Torsemide 10 mg + Spironolactone 50 mg Simvastatin 5 mg Simvastatin 10 mg Simvastatin 20 mg Simvastatin 40 mg Simvastatin 10 mg + Ezetimibe Simvastatin 20 mg+ Ezetimibe Telmisartan 20 mg Telmisartan 40 mg Telmisartan 80 mg Diabetic Hypertension Diabetic Dyslipidemia Diabetic Dyslipidemia Diabetic Dyslipidemia Diabetic Dyslipidemia Diabetic Dyslipidemia Diabetic Dyslipidemia Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension

Telista H Telista RM 2.5 Telista - RM 5 Telista - AM

Telmisartan 40 mg + Hydrochlorothiazide 12.5 mg Telmisartan 40 mg + Ramipril 5 mg Telmisartan 40 mg + Ramipril 2.5 mg Telmisartan 40 mg + Amlodipine 5mg

Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension Diabetic Hypertension Diabetic Neuropathy Management

GABASTAR 300 Gabapentin 300 mg

GABASTAR SR Gabapentin sustained release 600 Diabetic Neuropathy Management 600 mg GABASTAR M GABASTAR MAX PREGASTAR 75 PREGASTAR 150 Gabapentin 300 mg + Mecobalamin 500 mcg Gabapentin 300 mg + Mecobalamin 500 mcg + ALA 100 mg Pregabalin 75 mg Pregabalin 150 mg Diabetic Neuropathy Management

Diabetic Neuropathy Management

Diabetic Neuropathy Management Diabetic Neuropathy Management Diabetic Neuropathy Management

PREGASTAR M Pregabalin 75 mg + Mecobalamin 75 750 mcg

PREGASTAR M Pregabalin 150 mg + Mecobalamin Diabetic Neuropathy Management 150 750 mcg DUMORE 20 DUMORE 30 DUMORE 60 DUMORE M 20 DUMORE M 30 DUMORE M 60 RIBAFIT Duloxetine 20 mg Duloxetine 30 mg Duloxetine 60 mg Duloxetine 20 mg + Mecobalamin 750 mcg Duloxetine 30 mg + Mecobalamin 750 mcg Duloxetine 60 mg + Mecobalamin 750 mcg Rimonabant 20 mg Diabetic Neuropathy Management Diabetic Neuropathy Management Diabetic Neuropathy Management Diabetic Neuropathy Management Diabetic Neuropathy Management Diabetic Neuropathy Management Diabetic Dyslipidemia

Vobit 0.2mg Vobit 0.3mg

Voglibose 0.2 mg Voglibose 0.3 mg

Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetes Management Diabetic Dyslipidemia Diabetic Dyslipidemia Diabetic Dyslipidemia

LUPSULIN N 40 Recombinant Human Insulin NPH LUPSULIN R 40 LUPSULIN M 30/70 LUPSULIN M 50/50 NOVASTAT 5 NOVASTAT 10 NOVASTAT 20 Recombinant Human Insulin Regular Recombinant Human Insulin 30% Regular & 70% NPH Recombinant Human Insulin 50% Regular & 50% NPH Rosuvastatin 5 mg Rosuvastatin 10 mg Rosuvastatin 20 mg

LupinRespira
Brand Name
BUDAMATE 100 TRANSCAPS(DPI) BUDAMATE 200 TRANSCAPS(DPI) BUDAMATE 400 INHALER(MDI)

Molecule
Formoterol 6 mcg & Budesonide 100 mcg Formoterol 6 mcg & Budesonide 200 mcg Formoterol 6 mcg & Budesonide 400 mcg

Therapy Segment
ICS+LABA ICS+LABA ICS+LABA ICS+LABA ICS+LABA ICS+LABA

BUDAMATE 100 Formoterol 6 mcg & Budesonide INHALER(MDI)BOX 100 mcg BUDAMATE 400 Formoterol 6 mcg & Budesonide TRANSCAPS (DPI) 400 mcg BUDAMATE 200 Formoterol 6 mcg & Budesonide INHALER(MDI)BOX 200 mcg

BUDATE 100 DPI BUDATE 100 MDI BUDATE 200 DPI BUDATE 200 MDI BUDATE 400 DPI

Budesonide 100 mcg Budesonide 100 mcg Budesonide 200 mcg Budesonide 200 mcg Budesonide 400 mcg

ICS ICS ICS ICS ICS ICS ICS ICS ICS+LABA

BUDATE 4X5X2ML Budesonide.5mg per 2 ML BUDATE FORTE 4X5X2ML Budesonide 1mg per 2ml

BUDATE 3X7X2ML Budesonide.5mg per 2 ML ESIFLO 125 Salmeterol 25 mcg & Fluticasone INHALER(MDI)BOX 125 mcg ESIFLO 250 INHALER(MDI) BOX ESIFLO500 TRANSCAPS Salmeterol 25 mcg & Fluticasone 250 mcg Salmeterol 50 mcg & Fluticasone 500 mcg

ICS+LABA

ICS+LABA ICS+LABA ICS+LABA INCS ANTICHOLINERGIC INCS BRONCHODILATOR BRONCHODILATOR BRONCHODILATOR + ANTOCHOLINERGIC BRONCHODILATOR + ANTOCHOLINERGIC BRONCHODILATOR

ESIFLOR 100 Salmeterol 50 mcg & Fluticasone TRANSCAPS (DPI) 100 mcg ESIFLOR 250 Salmeterol 50 mcg & Fluticasone TRANSCAPS (DPI) 250 mcg FLUTIFLO IPNEB 15ML MOMEFLO SALBAIR (MDI) SALBAIR TRANSCAPS(DPI) SALBAIR 1 TRANSCAPS(DPI) SALBAIR 1 TRANSCAPS(DPI) SALBAIR 1 FLUTICASONE 50 MCG EACH SPRAY Ipratropium 250 mcg/per ml mometasone 50 mcg in each spray Levo-Salbutamol 50 mcg Levo-Salbutamol 100 mcg Levosalbutamol 100mcg+ipratropium 40 mcg Levosalbutamol 100mcg+ipratropium 40 mcg salbutamol

TRANSPULE SALBAIR 15ML SALBAIR B (MDI)BOX

2,5mg+ipratropium500mcg for 2.5ml salbutamol 5mg/ml levosalbutamol 50mcg+beclomethasone 50mcg BRONCHODILATOR ICS+BRONCHODILATOR

SALBAIR B FORTE Levosalbutamol ICS+BRONCHODILATOR TRANSCAPS (DPI) 100mcg+beclomethasone200mcg SALBAIR B levosalbutamol 100+ TRANSCAPS (DPI) beclomethasone 100mcg SALBAIR I (MDI) BOX levosalbutamol 50 mcg+ipratropium 20 mcg ICS+BRONCHODILATOR ICS+ ANTICHOLINERGIC BRONCHODILATOR BRONCHODILATOR ANTICHOLINERGIC ANTICHOLINERGIC ANTICHOLINERGIC + LABA ANTICHOLINERGIC + LABA ANTIHISTAMINE+ INCS DRUG DELIVERY SYSTEM ANTILEUKOTRIENE ANTILEUKOTRIENE ANTILEUKOTRIENE ANTILEUKOTRIENE + BRONCHODILATOR ANTILEUKOTRIENE + ANTIHISTAMINE

SALBAIR levosalbutamol 50 mcg TRANSCAPS (DPI) SALBAIR TRANSPULES TIATE DPI TIATE MDI TIOMATE DPI TIOMATE MDI AZEFLO LUPIHALER TELEKAST 4MG TELEKAST 5MG TELEKAST 10 TELEKAST PLUS TELEKASTL salbutamol 2.5mg per 2.5 ml Tiotropium 18 mcg Tiotropium 9 mcg Tiotropium 18 mcg &Formoterol 12 mcg Tiotropium 9 mcg &Formoterol 6 mcg Azelastine 140 mcg + 50 mcg fluticasone each spray Advanced Mono Dose Device Montelukast Sodium Chewable Tablets 4 mg Montelukast Sodium Chewable Tablets 5 mg Montelukast Sodium Tablets 10 mg Montelukast 10 mg &Bambuterol 10 mg Montelukast 10 mg &Levocetirize 5 mg

LUDO 120 STERIO 4 STERIO 8 STERIO 16 DOXIFLO 400MG FORMOFLO 125 MDI FORMOFLO 250 MDI FORMOFLO 100 FORMOFLO 250 DUOMATE TRANSCAPS DUOMATE FORTE APTIVATE LCIN 250MG LCIN 500MG LCIN A STARCET 5MG STARCET A STARCET COLD LCF COUGH FORMULA LCF KID

MDI Dose Counter Methyl Prednisolone Tablets 4 mg Methyl Prednisolone Tablets 8 mg Methyl Prednisolone Tablets 16 mg Doxofylline tablets 400 mg Formoterol 6 mcg & Fluticasone 125 mcg Formoterol 6 mcg & Fluticasone 250 mcg Formoterol 6 mcg & Fluticasone 100 mcg Formoterol 6 mcg & Fluticasone 250 mcg Formoterol 6 mcg &Beclomathasone 200 mcg Formoterol 6 mcg &Beclomathasone 400 mcg 9 natural ingredients Levofloxacin 250 mg tablets Levofloxacin 500 mg tablets Levocetirizine 5 mg tablets levocetirizine 5 mg+ambroxol 75 tablets

DOSE COUNTER ORAL STEROID ORAL STEROID ORAL STEROID BRONCHODILATOR ICS+LABA ICS+LABA ICS+LABA ICS+LABA ICS+LABA ICS+LABA APPITIZER ANTIBIOTIC ANTIBIOTIC ANTIHISTAMINE ANTIHISTAMINE + MUCOLYTIC

Levocetrizine 2.5mg+paracetamol ANTIHISTAMINE + 500mg+psedoephradine 60 mg MUCOLYTIC+ANALGESIC Levosalbutamol 1mg+guaiphenesin 50 mg+ambroxol 15mg/5ml Levosalbutamol .5mg+guaiphenesin 50 COUGH FORMULA

COUGH FORMULA

mg+ambroxol 15mg/5ml INCS ICS LABA INTRANASAL CORTICOSTEROID INHALEDCORTICOSTEROID LONG ACTING BRONCHODILATOR -

MARKET SHARE OF LUPIN PHRMA

Lupin Q4 & FY 2008-09 Results - Consistent Performance & Solid Growth

Q4 2008-09 Consolidated Net Profits up 64.2% at Rs. 1574 million May 13, 2009, Mumbai, India
Leading transnational pharmaceutical major, Lupin Limited, reported an outstanding performance for the fourth quarter and financial year ended March 31st, 2009. These audited results were taken on record

by the Board of Directors at a meeting held in Mumbai today.

Key Highlights - Consolidated FY 08-09

y y y y y y

y y

y y y y y y

Net sales grew at 39.5% to Rs. 37759 million from Rs. 27064 million last year Net profit grew at 50.2% to Rs. 5015 million compared to Rs. 3338 mn in previous year (excluding IP income) EBITDA margin increased to 19.7% Exports up by 63.2% at Rs. 24701 mn Advanced markets sales (including Japan and ANZ) increased to 92% over last year and contributed 50% of the Net Sales for the year as against 36% in the previous year. Advanced Markets sales to US and EU grew at 70% to Rs.14310 million including API One of the fastest growing generic players in the US by prescriptions and the 9th largest in terms of total prescription base A basket of 22 products in the US with 8 market leaders Domestic Formulations Business grew at 24.6%% to Rs. 10,575 million. Lupins Japanese subsidiary, Kyowa contributed 12% of the overall revenues - Rs. 4424 million 28 ANDAs, 15 DMFs, 18 MAAs,6 EDMFs,3 COS, & 1 AU DMF were filed during FY 08-09. Four Major Acquisitions across Germany, Australia, South Africa and the Philippines Dividend Announcement of 125 %

Key Highlights Q4 FY 08-09

y y y

Net sales for Q4 FY 08-09 grew at 39% to Rs.10434 million. Advanced markets sales (U.S, EU & Japan) increased to 86 % at Rs 5681 million over Q4 FY 07-08 Net profit for Q4 FY 08-09 grew at 64.2% to Rs.1574 million compared to Rs. 959 million in Q4 FY 07-08

Commenting on Lupins performance, Dr. Kamal K Sharma, Managing Director, Lupin Limited, said, Lupins stellar performance reflects the strong business philosophy guiding us. Lupin has had a very strong year driven by growth and consistent performance across all business segments and markets: a strong business performance in the US, solid domestic growth & increased activity in all key markets. Lupins acquisitions have not only consolidated our existing presence in these markets but also leaves us strategically poised to further strengthening our position in the global generics and branded generics market. It has indeed been a year of many achievements and robust growth, and we are now strategically poised to not only address market needs but also maintain momentum and direction.

Financials:
Advanced markets US & Europe
Lupin continued its growth momentum in the US and Europe a healthy contribution of 36% to our total revenues at Rs. 13634 million. (Formulations)

USA:
Lupin Pharmaceuticals Inc., the companys US subsidiary, reported a stellar performance recording sales of Rs. 12563 million reflecting a growth of 74.4% as compared to Rs. 7205 million in FY 07-08. Lupins Generic and Branded business recorded exponential growth during the financial year. More importantly, FY 08-09 saw Lupin increasing its product portfolio in the branded generics segment through the launch of AeroChamber Plus. LPI forged a Strategic Alliance with Forest Laboratories, Inc.

for marketing and promoting AeroChamber Plus thereby extending Lupins presence in the respiratory segment and our franchise with Pediatricians which would also additionally open up new offices for Suprax. The brand business contributed 27% to the overall business at USD 74 mn The company further expanded and consolidated on its generic product portfolio with the launches of Ramipril caps, Divalproex DR tabs, Cefadroxil suspension and caps &Levetiracetam tabs. The Company now has a total of 22 products in the market, out of which 8 are market leaders. We are in the top 3 market positions by market share in 17 of these products (IMS Jan 09). Lupin today is one of the fastest growing generic players in the US based on growth in prescriptions and the 9th largest in terms of total prescription base. LPI was also recognized by Wal-Mart and awarded its prestigious Supplier Award of Excellence for the 2nd Quarter 2008 which is an acknowledgement of the inroads we have made into the US markets. During the year, the company demonstrated its capabilities on the Intellectual Property management front by successfully litigating and settling all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Ploughs "Clarinex" tablets. As per the terms of the settlement, Lupin Ltd. will be licensed under the relevant Desloratadine patents, and free to commercially launch its generic Desloratadine product, on July 1, 2012, or earlier in certain circumstances. Schering-Ploughs Clarinex tablets had U.S. sales of $329 million for the year 2007-MAT June 2008, according to IMS Health. Lupin also received the final approval for the Companys Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg, 500mg, 750 mg and 1000 mg from the U.S. Food and Drug Administration (USFDA). Commercial shipments of the product have commenced. LupinsLevetiracetam tablets are the AB-rated generic equivalent of

UCB Pharmaceuticals Keppra tablets, indicated as adjunctive therapy in the treatment of certain types of seizures associated with epilepsy. Keppra tablets had annual sales of approximately $ 1.2 billion (USD) for the twelve months ended September 2008, based on IMS Health sales data.

Europe:
Lupin further strengthened its presence in the European Union by completeing its acquisition of HormosanPharma GmbH (Hormosan), a German generics company specialized in the supply of pharmaceutical products for the Central Nervous System (CNS). We also recorded our first strategic win in the German market through Hormosan in the next two quarters having received information on the results of the AllgemeineOrtskrankenkassen (AOK) Tender, pursuant to 130a SGB V. Hormosan has been offered to supply Setraline in all 5 regions of Germany covering all AOK-insured persons. Hormosan has a strong brand identity in the German generics market through its strong patient compliance message, essential for patients within the CNS sector. Lupin also made strategic inroads into the French market by launching CefpodoximeProxetil suspension in Q3. CefpodoximeProxetil has over 60 % market share in France.

AAMLA Japan:
Kyowa, the Companys subsidiary in Japan posted robust net sales of Rs. 4424 mn contributing 12% of Lupins Revenues having grown at over 21 % YoY Our products like Amlodipine Amel continues to maintain majority market share and Risperidone Amel, which was launched last year,

continue to exhibit market leadership in unit terms.

South Africa
Lupin clocked in revenues of Rs 919 million after having acquired an equity stake in Pharma Dynamics (PD) in South Africa in September 08. Pharma Dynamics is one of the fastest growing generic companies in South Africa growing at around 30 % for FY 08-09 with a clear leadership in the cardiovascular segment. PD is ranked number 6 amongst generic companies in South Africa. The South African Generics Market is currently valued at close to 800 Million USD and growing rapidly

Phillipines
In March 2009 the Company acquired a majority stake in MulticarePharmaceuticals Phillipines, Inc. (MC) in Phillipines. MC is a premium branded generics company with a strong position in womens health and child care segment.

ANZ
The Company continued its focus on this important market with aggressive filings in Australia, taking the cumulative MAA filings to 24 till date of which 18 have been approved.

Emerging Markets India

Domestic Formulations forms a very important part of Lupins overall growth. In the current financial year, it contributed about 28% of the net sales at Rs 10,575 million as against Rs. 8,487 million registering a growth of 24.6% over the previous year. This growth was driven by the good performance in the CVS,

Diabetes, CNS, Asthma and Gastro therapy Segments. The divisions catering to branded segments continued to outpace the industry growing over 27%. Lupin has maintained its leadership in Anti-TB segment and has secured a double digit market share in the antiasthma market riding high on the strengths of its offering in this segment. Research and Development Research & Development has always been a strategic and key focus area for Lupin and this year 2008-09 was no exception with 6% of the sales earmarked for R&D and related spends. The year 2008-09 was a landmark year with Lupin filing 28 Abbreviated New Drug Application (ANDA) with the USFDA, 11 DMFs, 15 MAAs and two EDMFs during the year. The cumulative ANDA filings stood at 90 with 34 approvals granted by the USFDA. Lupin also received the final approval for the Companys Abbreviated New Drug Application (ANDA) for Levetiracetam Tablets 250mg, 500mg, 750 mg and 1000 mg from the U.S. Food and Drug Administration (USFDA) during the quarter. Other The USFDA issued a warning letter for the Cephalosporin facility of the Mandideep plant. The facility was inspected in November, 2008 for a routine GMP inspection. As a result Lupin had received 15 procedural observations. Lupin responded to the observations in December and provided corrective actions for each of the responses. The warning letter was issued to provide Lupin with an opportunity to submit additional documentation and explanation to a few selected observations where the FDA felt that the initial responses were inadequate and could be strengthened by further evidence of compliance with enhanced documentation practices.

All products maintain their approved status. Lupin manufacturing will not be disrupted and it will continue to provide quality products to customers without interruption. Lupin has formulated a strategy to address and resolve the USFDA and is confident of being able to satisfy the USFDAs observations expeditiously. Dividend-In view of excellent performance, the Board of Directors recommended a dividend of 125 % i.eRs. 12.50 per equity share of the face value of Rs. 10 each.

COMPANY MANUFACTURING/R&D
Business Development
Lupin was founded to meet the very basic need for effective treatment of tuberculosis. Our success is tied to continually meeting the need for basic products to promote human health. Our company strives to bring important new products to market each year. We expect our products to come from:
y y y

In-house product development; Licensing and acquisitions; Marketing alliances.

Lupin is also seeking to be the partner of choice for product development. Our scientists apply know how and expertise to develop NCEs or to solve difficult formulation challenges. We strive for continued growth and are avidly interested in learning about prospective opportunities in the specialty pharmaceutical market. We are also open to collaborating to develop innovative products formulated with Lupins drug delivery and taste masking technology. Our API business unit is seeking partners for Lupin developed API's. Please contact us regarding business or product collaboration opportunities

Phone: 410-576-2000 Facsimile: 410-576-2221

Email: admin@lupinusa.com

NEW Products

Generics
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil. Since then we have received more than a dozen FDA approvals. Six of Lupin's 14 ANDA approvals were the first granted by the US FDA, reinforcing our ability to submit high quality dossiers and gain on time approvals. We are vertically integrated, from process development of the API to the submission of dossiers for finished dosages. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive prices. Our integrated manufacturing capability provides a portfolio of the highest quality generic products. Expanding the product portfolio, Lupin

Pharmaceuticals, Inc. is geared to file 15 or more ANDAs per year in some of the following areas: Oral and injectable cephalosporins; Cardiovascular; Controlled release ANDAs; Paragraph IVs. Our oral and injectable cephalosporin facilities, US FDA approved manufacturing sites and the new tablet and capsule facility in Goa, allow us to file and manufacture a wide range of finished products for the US market.

Newsroom
Lupin receives FDA approval for Imipramine Pamoate Capsules View Apr 16, 2010

Lupin receives FDA tentative approval for Eszopiclone tablets View

Mar 20, 2010

Lupin receives FDA approval for Amlodipine/Benazepril Feb 08, 2010 capsules View

Lupin receives FDA approval for Perindopril Erbumine Tablets View

Jan 28, 2010

Lupin receives FDA tentative approval for MemantineHCl Jan 19, 2010 tablets View

Lupin is granted USFDA approval for Levetiracetam Tablets View

Jan 16, 2009

Lupin Receives Supplier Award of Excellence from Wal-Mart View

Sept 17, 2008

Lupin receives USFDA approval for Divalproex Sodium Delayed-Release Tablets View

July 29, 2008

Lupin appoints New NCE Research Head. View

June 26, 2008

Lupin Enters Into Marketing Alliance with ASCEND

June 23,

Therapeutics for SUPRAX 400 mg Tablets in the U.S. View

2008

Lupin receives USFDA approval for Escitalopram Oxalate Tablets View

June 16, 2008

Lupin launches Ramipril capsules View

June 10, 2008

Lupin receives USFDA approval for Topiramate Tablets May 29, 2008 View

Lupin Receives Best New Manufacturer of the Year Award from AmerisourceBergen View

July 30, 2007

Lupin receives final approval for Amlodipine Tablets View

July 12, 2007

Lupin announces Final Approval of Trandolapril Tablets June 13, 2007 View

Lupin Receives US FDA Approval for ZiprasidoneHCl Capsules View

May 22, 2007

Lupin Announces Final FDA Approval of Cefdinir for Oral Suspension, 250 mg/5 mL, Launches Entire Product Family. View

May 8, 2007

Lupin Receives US FDA Approval for Novel Formulation April 12, of Suprax Suspension 2007 View

Lupin Receives US FDA Approval for Sertraline. View

February 7, 2007

Products

Specialty A commitment To Caring For Kids

Lupin Pharmaceuticals, Inc. is committed to developing a branded pharmaceutical presence for pediatric practice in the US market. We are committed to identifying, developing and marketing prescription drugs for children of all ages. Lupin has created a dedicated national sales force to call upon pediatricians. Lupin Pharmaceuticals, Inc., is very pleased to offer Suprax, an important anti-infective product in pediatric and other physician practices within the United States. Suprax is now available in tablets and suspension formulations. Lupin Pharmaceuticals, Inc., has an exclusive license in the United States to use the Suprax trademark. We plan to expand our family of pediatric products to help meet needs of children. Our focus is on in-house product development with our proprietary oral controlled release and taste masking platforms. Lupin Pharmaceuticals, Inc. is also open to marketing alliances, and to licensing/acquisitions.

API

Lupin is recognized as a leading manufacturer of cephalosporin APIs, with FDA approval to manufacture complex oral and injectable cephalosporins. Lupin is fast gaining share in the cardiovascular segment manufacturing a wide range of ACE-inhibitors and cholesterol reducing agents. Lupins capabilities in sterile processing, synthetic process development and fermentation skills coupled with its intellectual property strengths, puts the company in a very strong position to offer a diverse portfolio of niche APIs to its customers.

SHARE IN MARKET ANNUL

Lupin Limited (NSE:EQLUPIN)

Lupin Limited is amongst the top six pharmaceutical companies in India in terms of revenue. The Company is the worlds largest manufacturer of Tuberculosis drugs.
Business Overview

Headquartered in Mumbai, India Lupin Limited is a transnational pharmaceutical company producing generic and branded formulations and Active Pharmaceutical Ingredients(APIs)[1]The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs(Non-steroidal anti-inflammatory drugs)[1]

Net profit for Q4 FY 08-09 grew at 64.2% at Rs. 1574 million compared to Rs 959 million in Q4 FY 07-08.Net sales growth for Q4 FY 08-09 was 39% at Rs. 10434 million.[1]

Business and Financial Metrics

Lupin Limited's share holding pattern
[4]

Entity

Percentage

Indian Promoters 50.62% Foreign Promoters 0.01% FII's 11.15% General Public9.21%Banks Fin. Inst. and Insurance09.76%Private Corporate Bodies1.48%NRI's/OCB's/Foreign Others2.90%Others0.13%

Business Segments
Formulations Active Pharamceutical Ingredients and Intermediates ROCE is comparable to the best in the segment at 33%[6]

Competition
The pharmaceutical industry is characterized by rapid advances in scientific knowledge and ability to discover new drugs.The industry is therefore led by large manufacturers and marketers of drugs investing heavily in research & development, having clinical testing, marketing and distributing capabilities[7].Some of the main competitors of Lupin are:

Sun PharamceuticalsIndustires - It is No. 1 in India in speciality therapy areas like psychiatry, neurology, cardiology, gastroenterology, diabetology and respiratory.[8].It has brands in 30 markets worldwide and also has a generic presence in the U.S. with Caraco Pharm Labs, Sun Pharmaceutical Industries Inc (subsidiary)[8]

[9] Cipla - Cipla is a leader in the domestic retail pharmaceutical market. It also exports raw materials,

intermediates, prescription drugs, over-the-counter products, and veterinary products to some 180 countries around the world.[9]

GlaxoSmithKline - It is one of the oldest pharma companies in India and with a turnover of Rs. 1500 crore is one of the market leaders(market share) in India with a share of 6.2 per cent infectives, dermatologicals and pain management drugs
[11] [10]

Its main portfolios consists of anti-

Dr. Reddy's Laboratories - It is a global pharmaceutical company with it's headquarters in India and a presence in more than 100 countries.[12]In India it the biggest drug maker by sales[13]

Comparison with the competitors:

Financial metrics FY2008 Name Lupin Sun Pharma Cipla Yr Ended Market Capitalization in Rs Cr Sales Turnover in Rs Cr Net Profit in Rs Cr Mar '08 6,473.42 Mar '08 26,975.87 Mar '08 17,947.66 9,992.41 2,661.62 2,427.35 4,293.95 1,762.64 3,428.40 443.38 1,014.04 701.43 576.57 475.22

GlaxoSmithKline Dec '07 DrReddys Labs

Mar '08 9,662.53

Market Share on the basis of Retail Sales Due to high level of fragmentation none of the Pharma Companies had more than 6% of the total market on the basis of the total retail sales.[15]

KEY DEVELOPMENTS FOR LUPIN PHARMACEUTICALS, INC.

Lupin Pharmaceuticals, Inc. Gets US FDA Nod for Anti-Depressant
04/20/2010

Lupin Pharmaceuticals, Inc. announced that it has been granted final

approval from the Food and Drug Administration (FDA) for the capsules in strengths of 75 mg, 100 mg, 125 mg and 150 mg. The drug is recommended for relieving depression symptoms. Lupin's Imipramine Pamoate capsules are generic equivalent of Mallinckrodt's Tofranil-PM. The drug had an annual sales of about $39 million for the year ended December, 2009.
Lupin Receives FDA Tentative Approval for Eszopiclone Tablets 03/22/2010

Lupin Pharmaceuticals, Inc. announced that it has received tentative approval for the Company's Abbreviated New Drug Application (ANDA) for Eszopiclone tablets, 1 mg, 2 mg and 3 mg from the U.S. Food and Drug Administration (USFDA). The company's Eszopiclone tablets are the ABrated generic equivalent of Sepracor's LUNESTAR tablets, indicated for the treatment of insomnia. The brand product had annual sales of approximately $761 million for the twelve months ended December 2009, based on IMS Health sales data. The product will be introduced in the market through LPI's strong network of national wholesalers and pharmacy chains post patent expiry in 2012.
Bayer AG Sues Lupin Pharmaceuticals in Patent Dispute over Oral Solution of the Antibiotic Cipro 03/9/2010

Bayer AG is suing Lupin Pharmaceuticals, Inc. in a patent dispute over the oral solution of the antibiotic Cipro. Lupin informed Bayer Schering Pharma and Bayer HealthCare Pharmaceuticals that it had filed an ANDA to manufacture a generic Cipro (ciprofloxacin) oral solution in 250 mg/5 mL and 500 mg/5 mL strengths before patent protection ends